- Home
- TTAN vs LEGN Comparison
TTAN vs LEGN Comparison
Compare TTAN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTAN
- LEGN
- Stock Information
- Founded
- TTAN 2012
- LEGN 2014
- Country
- TTAN United States
- LEGN United States
- Employees
- TTAN N/A
- LEGN N/A
- Industry
- TTAN
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- TTAN
- LEGN Health Care
- Exchange
- TTAN NYSE
- LEGN Nasdaq
- Market Cap
- TTAN 10.2B
- LEGN 7.0B
- IPO Year
- TTAN 2024
- LEGN 2020
- Fundamental
- Price
- TTAN $123.03
- LEGN $31.08
- Analyst Decision
- TTAN Buy
- LEGN Strong Buy
- Analyst Count
- TTAN 14
- LEGN 13
- Target Price
- TTAN $118.23
- LEGN $79.42
- AVG Volume (30 Days)
- TTAN 500.0K
- LEGN 1.6M
- Earning Date
- TTAN 06-05-2025
- LEGN 05-13-2025
- Dividend Yield
- TTAN N/A
- LEGN N/A
- EPS Growth
- TTAN N/A
- LEGN N/A
- EPS
- TTAN N/A
- LEGN N/A
- Revenue
- TTAN $771,878,000.00
- LEGN $728,303,000.00
- Revenue This Year
- TTAN $19.04
- LEGN $65.96
- Revenue Next Year
- TTAN $13.40
- LEGN $52.55
- P/E Ratio
- TTAN N/A
- LEGN N/A
- Revenue Growth
- TTAN 25.64
- LEGN 112.46
- 52 Week Low
- TTAN $79.81
- LEGN $29.27
- 52 Week High
- TTAN $128.16
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- TTAN N/A
- LEGN 39.41
- Support Level
- TTAN N/A
- LEGN $30.25
- Resistance Level
- TTAN N/A
- LEGN $33.30
- Average True Range (ATR)
- TTAN 0.00
- LEGN 1.53
- MACD
- TTAN 0.00
- LEGN -0.18
- Stochastic Oscillator
- TTAN 0.00
- LEGN 26.21
About TTAN SERVICETITAN INC
ServiceTitan Inc is an end-to-end technology platform built for contractors to transform the performance of their businesses. The Company's platform provides business owners, technicians, customer service representatives and other key office staff with technology tools designed to help customers grow revenue, drive operational efficiencies, deliver a superior end-customer experience and monitor key business drivers in real-time. The Company also has subsidiaries in Yerevan, Armenia and British Columbia, Canada that primarily serve as research and development and support centers.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.